{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:34:47Z","timestamp":1771014887524,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T00:00:00Z","timestamp":1470268800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2633-2","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T00:42:13Z","timestamp":1470271333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2418-660X","authenticated-orcid":false,"given":"Marjolijn","family":"van Keep","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Gairy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divyagiri","family":"Seshagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pushpike","family":"Thilakarathne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,4]]},"reference":[{"issue":"9","key":"2633_CR1","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the Uk\u2019s Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575\u201384.","journal-title":"Br J Cancer"},{"issue":"4","key":"2633_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/bjh.12046","volume":"159","author":"P McKay","year":"2012","unstructured":"McKay P, Leach M, Jackson R, Cook G, Rule S. British Committee for Standards in Haematology. Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol. 2012;159(4):405\u201326.","journal-title":"Br J Haematol"},{"issue":"1","key":"2633_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.critrevonc.2011.05.001","volume":"82","author":"S Cortelazzo","year":"2012","unstructured":"Cortelazzo S, Ponzoni M, Ferreri AJ, Dreyling M. Mantle cell lymphoma. Crit Rev Oncol Hematol. 2012;82(1):78\u2013101.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2633_CR4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/107327481201900307","volume":"19","author":"BD Shah","year":"2012","unstructured":"Shah BD, Martin P, Sotomayor EM. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control. 2012;19(3):227\u201335.","journal-title":"Cancer Control"},{"issue":"Suppl 3","key":"2633_CR5","doi-asserted-by":"publisher","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","volume":"25","author":"M Dreyling","year":"2014","unstructured":"Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii83\u201392.","journal-title":"Ann Oncol"},{"issue":"1","key":"2633_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","volume":"125","author":"E Campo","year":"2015","unstructured":"Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. Blood. 2015;125(1):48\u201355.","journal-title":"Blood"},{"key":"2633_CR7","volume-title":"Mantle cell lymphoma facts","author":"Leukemia & Lymphoma Society","year":"2014","unstructured":"Leukemia & Lymphoma Society. Mantle cell lymphoma facts. 2014. [5 December 2014]. Available from: http:\/\/www.lls.org\/content\/nationalcontent\/resourcecenter\/freeeducationmaterials\/lymphoma\/pdf\/mantlecelllymphoma.pdf ."},{"issue":"4","key":"2633_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/annonc\/mds643","volume":"24","author":"M Dreyling","year":"2013","unstructured":"Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24(4):857\u201377.","journal-title":"Ann Oncol"},{"issue":"4","key":"2633_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3109\/10428194.2012.733882","volume":"54","author":"M Dreyling","year":"2013","unstructured":"Dreyling M, Kluin-Nelemans HC, Bea S, Klapper W, Vogt N, Delfau-Larue MH, et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma. 2013;54(4):699\u2013707.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2633_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558\u201365.","journal-title":"Blood"},{"issue":"6","key":"2633_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1200920","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520\u201331.","journal-title":"N Engl J Med"},{"key":"2633_CR12","volume-title":"Velcade mantle cell lymphoma health technology assessment advisory board summary","author":"Janssen-Cilag Ltd","year":"2014","unstructured":"Janssen-Cilag Ltd. Velcade mantle cell lymphoma health technology assessment advisory board summary. 2014."},{"issue":"4","key":"2633_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4):511\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2633_CR14","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002;20(5):1288\u201394.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2633_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00277-003-0774-2","volume":"83","author":"G Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol. 2004;83(2):71\u20137.","journal-title":"Ann Hematol"},{"issue":"9","key":"2633_CR16","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantiy improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984\u201392.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2633_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2141.2006.05970.x","volume":"133","author":"MB Moller","year":"2006","unstructured":"Moller MB, Pedersen NT, Christensen BE. Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index. Br J Haematol. 2006;133(1):43\u20139.","journal-title":"Br J Haematol"},{"issue":"9873","key":"2633_CR18","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310.","journal-title":"Lancet"},{"issue":"26","key":"2633_CR19","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol. 2005;23(26):6409\u201314.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2633_CR20","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","volume":"372","author":"T Robak","year":"2015","unstructured":"Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944\u201353.","journal-title":"N Engl J Med"},{"key":"2633_CR21","volume-title":"Guide to the methods of technology appraisal","author":"National Institute for Health and Care Excellence (NICE)","year":"2013","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. 2013. [1 September 2014]. Available from: https:\/\/www.nice.org.uk\/article\/pmg9\/resources\/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf ."},{"key":"2633_CR22","volume-title":"TA370: Bortezomib for previously untreated mantle cell lymphoma","author":"National Institute for Health and Care Excellence (NICE)","year":"2015","unstructured":"National Institute for Health and Care Excellence (NICE). TA370: Bortezomib for previously untreated mantle cell lymphoma. 2015. [29 January 2016]. Available from: http:\/\/www.nice.org.uk\/guidance\/ta370 ."},{"key":"2633_CR23","volume-title":"National Institute for Health and Clinical Excellence (NICE) DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data","author":"N Latimer","year":"2011","unstructured":"Latimer N. National Institute for Health and Clinical Excellence (NICE) DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2011. [2 March 2015]. Available from: http:\/\/www.nicedsu.org.uk\/NICE%20DSU%20TSD%20Survival%20analysis.updated%20March%202013.v2.pdf ."},{"key":"2633_CR24","unstructured":"Janssen Research & Development. A randomized, open-label, multicenter Phase III study of the combination of rituximab, cyclophosphamide, doxorubicin, VELCADE, and prednisone (VcR-CAP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with newly diagnosed mantle cell lymphoma who are not eligible for a bone marrow transplant. Clinical Study Report. Data on file 2014."},{"key":"2633_CR25","unstructured":"Amin A, Taylor R, Alonso A, Schwenke C, Gaudig M, Gaugris S, et al. Progression-free survival as a surrogate endpoint for overall survival in relapsed-refractory mantle cell lymphoma.\u00a0Poster presented at: 19th European Hematology Association Congress. Milan; 2014.\u00a0Available from:\u00a0 http:\/\/learningcenter.ehaweb.org\/eha\/#!*menu=6*browseby=7*sortby=1*media=2*ce_id=717 ."},{"key":"2633_CR26","doi-asserted-by":"crossref","unstructured":"Pan L, Guthrie KA, Till BG, Press OW, Pagel JM, Petersdorf S, et al. The mantle cell lymphoma international prognostic index (MIPI) at diagnosis is associated with survival of mantle cell lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Poster presented at:\u00a050th American Society of Hematology (ASH) Annual Meeting & Exposition. San Fransisco: Blood; 2008. p. 112:1143.","DOI":"10.1182\/blood.V112.11.1143.1143"},{"key":"2633_CR27","volume-title":"England and Wales National Life Tables, 1980-82 to 2010-12","author":"Office for National Statistics","year":"2014","unstructured":"Office for National Statistics. England and Wales National Life Tables, 1980-82 to 2010-12. 2014. [6 May 2014]. Available from: http:\/\/webarchive.nationalarchives.gov.uk\/20160105160709\/http:\/\/www.ons.gov.uk\/ons\/dcp171778_356439.pdf ."},{"key":"2633_CR28","doi-asserted-by":"crossref","unstructured":"Hatswell AJ, Porter J, Hertel N, Lee D. The cost of costing treatments incorrectly: errors in the application of drug prices in economic models due to differing patient weights.\u00a0Poster presented at: ISPOR 17th Annual European Congress. Amsterdam; 2014.\u00a0Available from:\u00a0 http:\/\/www.ispor.org\/research_pdfs\/48\/pdffiles\/CN4.pdf .","DOI":"10.1016\/j.jval.2014.08.568"},{"key":"2633_CR29","unstructured":"National Health Service (NHS). . 2013. [updated 22 January 20152 March 2015]. Available from: https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2013-to-2014 ."},{"key":"2633_CR30","volume-title":"Unit costs of health and social care 2014 Cantebury, University of Kent: Personal Social Services Research Unit","author":"L Curtis","year":"2014","unstructured":"Curtis L. Unit costs of health and social care 2014 Cantebury, University of Kent: Personal Social Services Research Unit. 2014. [2 March 2015]. Available from: http:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/2014\/ ."},{"key":"2633_CR31","unstructured":"Monthly Index of Medical Specialities (MIMS). 2015. Available from: http:\/\/www.mims.co.uk\/ ."},{"key":"2633_CR32","volume-title":"Drugs and pharmaceutical electronic market information (eMit)","author":"Department of Health","year":"2014","unstructured":"Department of Health. Drugs and pharmaceutical electronic market information (eMit). 2014. [4 March 2015]. Available from: https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit ."},{"key":"2633_CR33","volume-title":"NHS blood and transplant price list 2014-2015","author":"National Health Service (NHS)","year":"2014","unstructured":"National Health Service (NHS). NHS blood and transplant price list 2014-2015. 2014. [2 March 2015]. Available from: http:\/\/hospital.blood.co.uk\/products\/ ."},{"issue":"2","key":"2633_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1600-0609.2005.00438.x","volume":"75","author":"J Doorduijn","year":"2005","unstructured":"Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P. Self-reported quality of life in elderly patients with aggressive non-Hodgkin\u2019s lymphoma treated with CHOP chemotherapy. Eur J Haematol. 2005;75(2):116\u201323.","journal-title":"Eur J Haematol"},{"issue":"8","key":"2633_CR35","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","volume":"124","author":"A Abrahamsson","year":"2014","unstructured":"Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D\u2019Amore F, et al. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood. 2014;124(8):1288\u201395.","journal-title":"Blood"},{"issue":"8","key":"2633_CR36","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3109\/10428194.2012.656628","volume":"53","author":"R Chandran","year":"2012","unstructured":"Chandran R, Gardiner SK, Simon M, Spurgeon SE. Survival trends in mantle cell lymphoma in the United States over 16\u00a0years 1992-2007. Leuk Lymphoma. 2012;53(8):1488\u201393.","journal-title":"Leuk Lymphoma"},{"key":"2633_CR37","volume-title":"TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation","author":"National Institute for Health and Care Excellence (NICE)","year":"2014","unstructured":"National Institute for Health and Care Excellence (NICE). TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. 2014. [25 September 2015]. Available from: http:\/\/www.nice.org.uk\/guidance\/ta311 ."},{"key":"2633_CR38","volume-title":"TA299: Bosutinib for previously treated chronic myeloid leukaemia","author":"National Institute for Health and Care Excellence (NICE)","year":"2013","unstructured":"National Institute for Health and Care Excellence (NICE). TA299: Bosutinib for previously treated chronic myeloid leukaemia. 2013. [25 September 2015]. Available from: http:\/\/www.nice.org.uk\/guidance\/ta299 ."},{"key":"2633_CR39","volume-title":"TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia","author":"National Institute for Health and Care Excellence (NICE)","year":"2010","unstructured":"National Institute for Health and Care Excellence (NICE). TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia. 2010. [16 September 2015]. Available from: http:\/\/www.nice.org.uk\/guidance\/ta193 ."},{"key":"2633_CR40","volume-title":"TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer","author":"National Institute for Health and Care Excellence (NICE)","year":"2012","unstructured":"National Institute for Health and Care Excellence (NICE). TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer. 2012. [28 September 2015]. Available from: http:\/\/www.nice.org.uk\/guidance\/ta258 ."},{"key":"2633_CR41","volume-title":"TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia","author":"National Institute for Health and Care Excellence (NICE)","year":"2015","unstructured":"National Institute for Health and Care Excellence (NICE). TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia. 2015. [16 September 2015]. Available from: http:\/\/www.nice.org.uk\/guidance\/ta343 ."},{"key":"2633_CR42","volume-title":"Patient\u2019s age and treatment for haematological malignancy: a report from the Haematological Malignancy Research Network (HMRN)","author":"Haematological Malignancy Research Network (HMRN)","year":"2014","unstructured":"Haematological Malignancy Research Network (HMRN). Patient\u2019s age and treatment for haematological malignancy: a report from the Haematological Malignancy Research Network (HMRN). 2014. [26 February 2016]. Available from: https:\/\/hmrn.org\/publications\/reports ."},{"key":"2633_CR43","volume-title":"Bortezomib for previously untreated mantle cell lymphoma: Response to consultee and commentator comments on the draft remit and draft scope (pre-referral)","author":"National Institute for Health and Care Excellence (NICE)","year":"2015","unstructured":"National Institute for Health and Care Excellence (NICE). Bortezomib for previously untreated mantle cell lymphoma: Response to consultee and commentator comments on the draft remit and draft scope (pre-referral). 2015. [updated 7th May 2015; cited 2015 7 May 2015]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta370\/history ."},{"key":"2633_CR44","volume-title":"SMC advice 1075\/15: bortezomib 3.5mg powder for solution for injection (Velcade\u00ae)","author":"Scottish Medicines Consortium (SMC)","year":"2015","unstructured":"Scottish Medicines Consortium (SMC). SMC advice 1075\/15: bortezomib 3.5mg powder for solution for injection (Velcade\u00ae). 2015. [29 January 2016]. Available from: http:\/\/scottishmedicines.org.uk\/SMC_Advice\/Advice\/1075_15_bortezomib_Velcade\/bortezomib_Velcade ."},{"key":"2633_CR45","volume-title":"Improving choice at the end of life: a descriptive analysis of the impact and costs of the Marie Curie Delivering Choice programme in Lincolnshire: King\u2019s Fund","author":"R Addicot","year":"2008","unstructured":"Addicot R, Dewar S. Improving choice at the end of life: a descriptive analysis of the impact and costs of the Marie Curie Delivering Choice programme in Lincolnshire: King\u2019s Fund. 2008. [12 June 2015]. Available from: http:\/\/www.kingsfund.org.uk\/sites\/files\/kf\/improving-choice-end-of-life-descriptive-analysis-impact-costs-marie-curie-choice-programme-lincolnshire-rachael-addicot-steve-dewar-april-2008.pdf ."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2633-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2633-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2633-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2633-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T19:03:17Z","timestamp":1600974197000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2633-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,4]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2633"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2633-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,4]]},"article-number":"598"}}